Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Summary

A phase 1B study to explore the maximum tolerated dose (MTD) of dalpiciclib + chidamide in HR+/HER2- advanced breast cancer after the failure of CDK4/6 inhibitor therapy

Timeline

Start

2022-10-01

Primary completion

2025-12-30

Completion

2026-03-30

Publications

• Background Zhou J, Wu X, Du Y, Xiao J, Kang X, Chen J, Wang X, Tai Y, Bian L, Zhang S, Pang Z, Li Y, Jiang Z, Xu X, Wang T. Dalpiciclib plus chidamide in HR + /HER2-advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial. Nat Commun. 2026 Mar 20;17(1):5177. doi: 10.1038/s41467-026-70650-6.

Drugs

Indications